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A B S T R A C T
The use of long-acting injectable antipsychotics (LAIs) in schizophrenia is usually restricted to patients 
in long-term treatment, who prefer them to oral antipsychotics, and to patients with multiple relapses 
who have a history of non-adherence. However, preliminary evidence from patients in the early 
phases of the disease suggest that second generation LAIs may be superior to second generation oral 
medications with regard to the control of negative symptoms and psychosocial functioning. Moreover, 
several studies have found that psychiatrists are generally reluctant to prescribe LAI antipsychotics and 
under-estimate their acceptability by patients. Key elements to take into account when offering a LAI in 
the early course of schizophrenia should include their potential superiority in allowing early detection 
of non-adherence and in reducing the number of rehospitalisations and relapses.
© 2014 Elsevier Masson SAS. 
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1. Background
Schizophrenia has a chronic course in most cases characterised 
by recurrent episodes of acute psychosis alternating with periods 
of full or partial remission [1]. Patients require ongoing care 
for symptomatic control, relapse prevention and psychosocial 
rehabilitation [2].
Antipsychotic agents are the mainstay treatment of 
schizophrenia, as they have been shown in clinical trials and 
routine practice to decrease symptoms in the acute phase and also 
to prevent symptom recurrence and relapse in the longer term 
[3]. Long-acting injectable antipsychotics (LAIs) were developed 
several decades ago as a strategy to address partial or covert non-
adherence and to simplify complex medication schedules [4-6]. 
More recently, second generation antipsychotics (SGAs), have 
also become available as LAIs thus widening the therapeutic 
options [7-10]. In clinical practice, LAIs are prescribed to a low 
proportion of patients overall, and to an even lower proportion 
of first-episode patients [11-13]. In this review we describe the 
benefits and challenges associated with the use of antipsychotic 
LAI in patients in the early phase of the disease based on available 
evidence from the current literature.
2. Rationale for continuity of care in schizophrenia
The early phase of schizophrenia, comprising the first 2 to 
5 years after the first acute episode are considered to be crucial in 
determining long-term prognosis [14]. For instance, a minimum 
of 3 months sustained remission of both positive and negative 
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symptoms over the first 2 years of treatment is predictive of good 
functional recovery in first-episode patients [15]. Although most 
patients show a good initial response to antipsychotic treatment 
and achieve symptomatic remission after their first episode, 
recovery rates from both a clinical and a social perspective are 
generally low (13.5%) [16], and around 15% of patients have a 
chronic course of illness after relapse despite long-term treatment 
[17]. The incidence of acute episodes is particularly high in the 
first 5 years after the initial episode with a cumulative first relapse 
rate of 81.9%; of those 78% will have a second relapse, and a further 
86.2% of those will go on to have a third relapse [1]. Relapse risk 
is the same in remitted and non-remitted patients, and even 
with detailed assessment clinicians are not able to predict who 
will suffer a relapse [18]. Subsequent episodes are associated 
with a progressively longer time to achieve remission [19], worse 
treatment response, increased risk of symptom chronicity [20], 
and a gradual psychosocial deterioration [21].
The risk of relapse is mitigated by antipsychotic medication. The 
risk increases immediately after stopping medication and remains 
high over time [1], while maintaining antipsychotic treatment is 
associated with reduced risk of relapse, fewer hospitalizations, 
and better quality of life compared with placebo or no treatment 
[18]. Stopping antipsychotic medication after an acute episode or 
using medication intermittently during maintenance treatment is 
associated with increased risk of symptom worsening or relapse 
[22]. In patients who have remitted from a first episode, the mean 
one-year risk of psychotic symptom recurrence after medication 
discontinuation is 77% compared to 3% under maintenance 
treatment [23]. Moreover, after stopping medication, recurrence 
of psychotic symptoms usually occurs within a short period of 
time (16 days on average), even in patients with optimal outcome, 
and does not depend on the time to achieve remission or the 
length of remission [17,24,25].
The consequences of relapse faced by patients include 
the risk of harming themselves or others, impoverishment in 
personal relationships, discontinuation of education or work, 
and stigmatization, all leading to loss of self-esteem and reduced 
quality of life [26,27]. Relapses often have a negative emotional 
and financial impact on families and caregivers, and are associated 
with risk of rehospitalisation and high costs due to increased 
healthcare resource utilization [28-32].
3. Challenges of continuity of therapy for early episode 
patients
Despite general agreement on the need for continued, long-
term treatment for relapse prevention, non-adherence to oral 
medication is a well-known problem that occurs regardless of 
the type of antipsychotic prescribed, first or second generation 
[33-35]. Partial and complete non-adherence are recognised as 
strong predictors of relapse in patients treated after their first-
episode [1,36,37]. The discontinuation rates of oral antipsychotics 
in chronic schizophrenia have been estimated to be as high as 
74% after 18 months of therapy [38]. In first-episode about 46% 
continued their initial treatment for 30 days or longer [13], and 
42% discontinued treatment within 1 year [39]. Risk factors for 
non-adherence may be patient-related (e.g. impaired insight or 
substance abuse); environment-related (e.g. stigmatization or 
poor social and familial support); physician-related (e.g. poor 
relationship or contact with the therapist); and treatment-related 
(e.g. lack of efficacy or complex medication schedule) [40]. A recent 
systematic review on medication adherence in schizophrenia found 
that lack of insight, mistrust of the effectiveness of medication 
and substance abuse were the key drivers, and greater risk of 
relapse, hospitalization and suicide were the key consequences 
[41]. Finally, subjective ratings by psychiatrists, chart reviews, and 
self-reports by patients or relatives, show that adherence to oral 
medication is overestimated and that non-adherence is often not 
accurately identified [40].
Strategies to improve adherence include psychosocial inter-
ventions (e.g. psychoeducation, compliance therapy, and cognitive 
adaptation therapy), programmatic strategies (e.g. directly 
observed therapy [DOT] programs based on the direct observation 
of patients taking their medications), and interventions related 
to pharmacotherapy (e.g. close monitoring for medication side 
effects such as weight gain, sedation or extrapyramidal symptoms), 
simplification of medication regimens (e.g. considering agents 
with longer plasma half-lives or using medications with once-
daily dosing), and switching to LAI antipsychotics [42]. Different 
approaches may be necessary to improve adherence depending on 
the patient, since non-adherence can be non-intentional (when 
the patient deviates from dosage or timing), related to cognitive 
impairment, or intentional (leading to overt or covert full or 
partial non-adherence), related to poor insight [43-45].
4. Place of LAI antipsychotics in early stages of schizophrenia
LAI antipsychotics are recommended by most evidence-based 
clinical guidelines for patients who need maintenance treatment 
and explicitly prefer them over oral antipsychotics, and in patients 
with multiple relapses who have a history of non-adherence 
[22,46,47]. However, the Texas Medication Algorithm Project 
(TMAP) for antipsychotics in schizophrenia [48], and the recent 
Canadian guidelines recommend the use of LAI antipsychotics 
in all phases of the disease, including the first 2 to 5 years [49]. 
Moreover, the recently published consensus-based guidelines 
for the use and management of LAI antipsychotics in clinical 
practice by the French Association for Biological Psychiatry and 
Neuropsychopharmacology (AFPBN) is the first to recommend 
systematic offering of LAI antipsychotics as first line treatment to 
schizophrenic patients who need maintenance treatment [50].
There is general reluctance in using LAI antipsychotics in 
routine clinical practice in first-episode patients. This reluctance 
may be present even when patients are considered poorly 
adherent [51]. More than 50% of patients are not offered the 
option of LAI antipsychotics [11,52]; and less than 30% of patients 
are prescribed LAIs in preference to oral antipsychotics [12,53-
55]. A recent study conducted in Germany found that clinicians 
were reluctant to prescribe LAI antipsychotics even when, by their 
own assessment, they suspected or anticipated non-adherence 
[56]. In the case of first-episode patients, a survey conducted in 
the UK reported that although half of the psychiatrists considered 
LAI antipsychotics as an option, less than 15% went on to 
prescribe LAIs [11-13]. Results from surveys of clinician attitudes 
conducted in 2007 and 2011 show that psychiatrists believe that 
patients with first-episode schizophrenia will probably reject 
LAI antipsychotics [11,12]. However, 73% of first-episode patients 
participating in a prospective trial accepted the recommendation 
to receive risperidone LAI (RLAI) [57]. Psychiatrists are also of the 
opinion that patients are difficult to convince because they have 
not yet experienced further relapses and that the availability of 
SGAs in LAI formulations is limited [12]. This latter concern has 
been addressed as several SGAs are now available as LAIs and data 
are accumulating on their efficacy and tolerability in first-episode 
patients [8,9,58].
5. Evidence for the use of LAI antipsychotics in first-episode 
schizophrenia
The evidence on the use of LAIs in first-episode or recent onset 
schizophrenia is far from conclusive as available studies have 
methodological limitations, particularly single-arm designs not 
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comparing oral antipsychotics with LAIs, the lack of differentiation 
between first and second generation LAIs, and confounding 
factors such as patient selection bias. For this review we only 
included studies comparing oral with first and second generation 
LAI antipsychotics, and only considered prospective naturalistic 
studies or randomised controlled trials. The search yielded a total 
of six studies that are summarised below; exhaustive information 
on all available studies can be found in other recent reviews [8-10].
Kim and colleagues compared relapse rates in patients 
diagnosed with first-episode schizophrenia and treated in an 
open label design either with RLAI (n = 22) or oral risperidone 
(n = 28)  [59]. At 1 and 2 years of follow-up, patients on RLAI had 
significantly lower relapse rates associated with longer periods 
of adherence and higher rates of adherence than patients on 
oral risperidone (68% vs. 32%). Additional benefits in the RLAI 
treated patients included greater reduction in the total Positive 
and Negative Syndrome Scale (PANSS) (10% vs. 2%; p = 0.001), and 
in the Clinical Global Impression-Severity (CGI-S) scale (10% vs. 
2.5%; p = 0.001) and greater functional improvement as measured 
by the General Assessment of Functioning (GAF) scale, with 
patients on RLAI showing an increase of 26% while patients on oral 
risperidone experienced a 0.5% improvement (p = 0.001).
A prospective randomised controlled study specifically com-
pared medication adherence during continuation treatment 
in first-episode patients (with ≤16 weeks of lifetime total anti-
psychotic medication exposure) following stabilization with 
oral risperidone [57]. Eleven patients received continuation 
treatment with oral risperidone while twenty-six were treated 
with RLAI. Almost three-quarters of patients (73%) accepted the 
recommendation to take RLAI. At 12 weeks, patients on RLAI were 
more likely to remain adherent than patients who remained on 
oral risperidone (89% vs. 59%: p = 0.035). There was no effect of 
RLAI on attitudes such as stigma, distress from side effects or 
problems with medication route. A subsequent follow-up of the 
same patients when they entered maintenance treatment [60] 
did not find any significant difference between RLAI and oral 
risperidone in time to initial non-adherence at 104 weeks and in 
attitudes to medication.
Another recent randomised controlled trial enrolled subjects 
in the early phase of the disease (schizophrenia diagnosis <3 years 
before study entry) who were either medication naïve or had 
been taking SGA (oral risperidone, olanzapine or quetiapine), 
and started maintenance treatment after stabilisation [61]. There 
were no differences in the CGI-S scores, PANSS total and positive 
symptoms subscale scores between patients randomised to RLAI 
(n = 42) or continuing on oral SGA (n = 35). However, the post-
hoc analysis on the change in PANSS negative symptom subscale 
scores showed differences between groups over time. Negative 
symptom scores decreased between baseline and study endpoint 
for both groups. During the stabilization phase, this decrease 
was greater and only significant in the RLAI- but not in the oral 
treatment group (p = 0.0007). However, from stabilisation to study 
end only the oral group showed a significant decrease in negative 
symptom scores (p = 0.005). There were no statistically significant 
differences between groups regarding time to stabilization, 
defined as at least 4 weeks of improved or stable values (< 4) on 
the CGI-S scale, or time to relapse according to Csernansky et al. 
criteria [62].
Besides studies focused on clinical outcomes, there may be 
evidence that improved medication adherence with LAI in early 
treatment of schizophrenia (less than 2 years from onset) may 
influence frontal lobe intracortical myelin and white matter 
volume [63,64]. Structural magnetic imaging data were acquired 
at baseline and at 6 months from patients randomized to RLAI 
(n = 9-11) or oral risperidone (n = 13) and healthy individuals 
(n = 12-14). Brain scans were analysed by a rater who was blinded 
to clinical and demographic characteristics of subjects. Frontal 
white matter volume remained stable over the 6-month study 
period in patients on RLAI but declined significantly in the oral 
risperidone group (p < 0.05). Of note, stability in frontal lobe 
white matter volume was associated with a faster reaction time 
in executive tasks of working memory (p = 0.045) and mental 
flexibility (p = 0.029). A further analysis focused on intracortical 
myelination (ICM) volume, which is known to decline with illness 
chronicity in schizophrenia [64]. Compared to baseline, patients 
treated with RLAI had increased ICM volume compared with 
controls (p = 0.005), while ICM volume the group treated with 
oral risperidone was comparable with controls. This preliminary 
evidence indicates that improved adherence associated with 
LAIs might mitigate disruption in myelination that has been 
hypothesised to contribute to the aetiology of schizophrenia.
6. Discussion
Effective treatment in schizophrenia is crucial in order to 
avoid the high risk of relapse after the first psychotic episode. 
Subsequent episodes have a negative impact in the patients’ 
quality of life and psychosocial functioning, are associated with 
negative long-term prognosis and gradual clinical deterioration 
and increase the health and economic burden to families and 
society. Although antipsychotic treatment helps to prevent 
relapse, regular medication adherence remains a major challenge, 
since about half of patients treated for their first-episode will 
discontinue initial treatment within a short time period.
LAIs have several advantages over oral antipsychotics: they 
are administered by a mental health professional which has the 
potential of increasing therapeutic contacts; allow for the easy 
and quick detection of non-adherence which facilitates immediate 
intervention; decrease the risk of accidental or deliberate 
overdose; the parenteral route avoids first-pass metabolism, 
which reduces the risk of drug-drug interactions; and last but 
not least, injections offer stable plasma concentrations that 
avoid high fluctuations and reduce risk of drug levels below or 
above the desired range. Compared with oral antipsychotics, 
meta-analyses based on randomised clinical trials (RCTs) [65-67] 
regarding the effectiveness of LAIs in patients at any stage of the 
disease suggest that LAIs reduce hospitalizations and may also 
reduce the rate of relapse. A meta-analysis of mirroring studies, 
which seem closer to a real-life clinical setting than RCTs, found 
substantial superiority of LAIs compared with oral antipsychotics 
in preventing hospitalization [67]. A significant advantage for 
LAIs versus oral antipsychotics was also observed in prospective 
and retrospective observational studies, which reflect real-life 
treatment settings in terms of discontinuation, relapse and 
rehospitalisation rates [68,69].
It is arguable whether RCTs are the most appropriate study 
design in comparing LAIs with oral antipsychotics in particular 
regarding adherence [70,71] since patients enrolled in such 
studies are likely to be more compliant with treatment advice 
in general. This is why alternative “effectiveness trials’’ closer to 
real-world conditions have been proposed. Ideally, they should 
be prospective, conducted at multiple sites, use broad inclusion 
criteria, require minimal data, focus on patients in a relatively early 
phase of illness, and follow patients for at least 2 years, with the 
primary outcome measures being relapse and/or hospitalisation 
[70].
Although we excluded several studies because of their 
methodological limitations they also support the role of LAIs 
in prevention of relapse and hospitalization [13,72,73]. The 
studies we included all compared risperidone LAIs with its oral 
formulation because data on more recently introduced SGA-LAIs 
such as olanzapine pamoate, paliperidone palmitate, and 
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aripiprazole depot are still lacking in first-episode or recent onset 
schizophrenia.
A noteworthy observation emerging from existing studies is 
that psychiatrists are reluctant to offer LAIs in patients at the early 
stages of their illness and tend to over-estimate potential objections 
by patients. Given that LAIs are likely to reduce hospitalisation and 
relapse they should be given due consideration in the treatment of 
early schizophrenia. Other potential beneficial effects on negative 
symptoms, cognitive deficits and brain plasticity should also be 
taken into account.
7. Conclusion
Newer, second generation antipsychotics (SGAs), including 
some LAIs, are an important and valuable treatment option for 
patients with first-episode or recent onset schizophrenia.
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